NHS England Low Priority Treatment - Aliskiren by all CCGs
Why it matters: NICE hypertension guidance states there is insufficient evidence of its effectiveness to determine its suitability for use in resistant hypertension. Whilst aliskiren has shown comparable efficacy to other antihypertensive agents in terms of blood pressure reduction, its effects on mortality and long-term morbidity are currently unknown.
Description: Cost of Aliskiren per 1000 patients
Performance: Loading...
Explore:
Tagged as: Cost Saving, Cardiovascular system, NHS England Investment and Impact Fund, NHS England Low Priority, NICE (or browse all measures)
CCGs are ordered by mean percentile over the past six months. Each chart shows the results for the individual CCG, plus deciles across all CCGs in the NHS in England.
View measure for NHS England combined →
Fetching data...